Comment: economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.

Similar Publications

• Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.

  Eric Q Wu, Andrew P Yu, Veronique Lauzon, Karthik Ramakrishnan, Maryna Marynchenko, Rym Ben-Hamadi, Steven Blum, M Haim Erder

• A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.

  In Kyoon Lyoo, Sujung Yoon, Tae-Suk Kim, Jaeuk Hwang, Jieun E Kim, Wangyoun Won, Sujin Bae, Perry F Renshaw

• FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

  Katarzyna A Ellsworth, Irene Moon, Bruce W Eckloff, Brooke L Fridley, Gregory D Jenkins, Anthony Batzler, Joanna M Biernacka, Ryan Abo, Abra Brisbin, Yuan Ji, Scott Hebbring, Eric D Wieben, David A Mrazek, Richard M Weinshilboum, Liewei Wang